|Articles|September 17, 2020
Resuming Operations After Fungal Contamination Following COVID-19 Shutdown
Author(s)Bioquell
Despite exhausting all disinfection methods after resuming operations this year, this international biologics provider repeatedly failed Environmental Monitoring test standards, delaying $5M in product release. See how Bioquell’s Rapid Bio Decontamination Service provided a fast, effective solution.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5